Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy (durvalumab - 750 mg) in subjects with liver-predominant, metastatic colorectal cancer (mCRC), which is mismatch repair proficient/microsatellite stable (pMMR/MSS).
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Adenocarcinoma,Colorectal Cancer,Colo-rectal Cancer,Rectal Cancer,Liver Neoplasms,Colorectal Carcinoma,Neoplasm Metastasis,Rectal Neoplasms,Liver Metastases,Neoplasms, Second Primary,Colon Cancer,Liver Metastasis Colon Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms,Colonic Neoplasms
PROVIDER: 2317731 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA